This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today?

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock has soared in 2018, as the company has generated excitement in early trials for its lead product candidate.

| More on:
The Motley Fool

Biotechnology has received renewed interest, as investors look for alternative growth opportunities with cannabis and other markets flailing so far in 2018.

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) is a clinical-stage biopharmaceutical company focused on the treatment of breast cancer. Shares of Zymeworks have soared 116.8% in 2018 as of close on April 30. The stock has recovered nicely from a steep drop in late May of 2017 and is now up 12.8% year over year. Zymeworks surged on news that Celgene Corporation had exercised its right to expand its collaboration agreements for the “research, development, and commercialization of biospecific antibody therapeutics using Zymeworks’ Azymetric platform.”

Zymeworks is engaged in phase one clinical trials for ZW25, its lead product candidate. ZW25 is an antibody designed to target gastric, ovarian, and breast cancer tumours. The product has yielded impressive results so far. Recently, the company announced that ZW25 had been selected for an oral presentation at the American Society of Clinical Oncology, which will be held in Chicago in early June.

Biotechnology stocks have been an explosive source of growth in recent years, but investors must also exercise a reasonable degree of caution with these speculative investments. The revenue garnered from established breast cancer drugs in the United States has generated a great deal of excitement over the prospects for Zymeworks.

Just how explosive is the growth of this industry?

The global breast cancer market has been fueled by rising healthcare expenditures, increased rates of obesity and diabetes in the population, and aging female demographics. In 2017, a report hosted by Research and Markets projected that the global breast cancer treatment market would reach $18.8 billion by 2025. This would represent a compound annual growth rate (CAGR) of 7.6% from 2017 to 2025.

Another report hosted by Global Market Insights projected that the breast cancer therapeutics market would reach $28 billion by 2024, representing a CAGR of 9%. This report cited the rising prevalence of breast cancer as well as the advancement of diagnostic and screening programs worldwide and sizable reimbursement policies. Whatever the case, the explosive potential of this market is clear. Does that mean you should invest in Zymeworks today?

Zymeworks released its 2017 fourth-quarter and full-year results on March 14. Highlights from 2017 included the results from ongoing phase 1 trials for ZW25, which we have covered already. In response to the successes, Zymeworks has expanded testing sites in the United States and Canada. Going forward, president and CEO Ali Tehrnani said that Zymeworks plans to complete enrollments in its phase one study in 2018 as well as file an Investigational New Drug application for ZW49, its second clinical compound.

In 2017, the company reported revenue of $51.8 million compared to $11 million in 2016. This was powered by the collection of a $50 million fee from its corporate partnership with Janssen. Zymeworks’s net loss in 2017 fell to $10.4 million compared to a $33.8 million loss in 2016. At the end of fiscal 2017, Zymeworks also reported it had $87.8 million in cash and cash equivalents.

The initial results for ZW25 have been promising, and further progress will undoubtedly generate excitement considering the enormous amount of revenue potential carried by breakouts in this industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Tech Stocks

Data center servers IT workers
Tech Stocks

Better Buy: Shopify Stock or Constellation Software?

Let's dive into whether Shopify (TSX:SHOP) or Constellation Software (TSX:CSU) are the better options for growth investors in this current…

Read more »

nvidia headquarters with nvidia sign in front
Tech Stocks

Nvidia Just Delivered a Beat-and-Raise Quarter. There’s 1 Red Flag Investors Shouldn’t Ignore.

The chipmaker continued to benefit from robust demand for artificial intelligence (AI). But can it last?

Read more »

GettyImages-1473086836
Tech Stocks

Why Super Micro Computer Stock Is Soaring Today

The volatile stock is getting a boost from Nvidia.

Read more »

Snowflake logo in snowflake office on wall_snowflake-1
Tech Stocks

Here’s Why Snowflake Stock Skyrocketed Today

Shares of the data company are up 32% for the day.

Read more »

man touching magnifying glass button on floating search bar internet google search engine
Tech Stocks

Why Alphabet Stock Was Sliding Today

The parent company of Google is facing heat from U.S. regulators.

Read more »

chart reflected in eyeglass lenses
Tech Stocks

Top Canadian AI Stocks to Watch in 2025

Celestica (TSX:CLS) stock and another Canadian AI stock are worth watching closely this holiday season.

Read more »

Nvidia Voyager Headquarters
Tech Stocks

Why Nvidia Stock Rallied (Again) on Tuesday

The chipmaker is expected to report earnings this evening.

Read more »

hand stacking money coins
Tech Stocks

3 Growth Stocks That Are Screaming Buys in November

The market might be soaring, but there are still lots of deals to be had. Here are three discounted stocks…

Read more »